伊贝沙坦治疗轻、中度原发性高血压临床观察

The efficacy and tolerability of irbesartan in patients with mild-moderate essential hypertension

目的 观察伊贝沙坦治疗轻、中度原发性高血压病人的疗效及耐受性。方法 用伊贝沙坦治疗 186例轻、中度原发性高压病人 12周。结果 病人于服药第 2、4、6、8、12周时 ,显效率分别为 4 0 3%、4 7 3%、5 4 4 %、6 3 2 %、71 1% ;有效率分别为 12 3%、17 3%、2 0 9%、2 2 6 %、2 3 3%。总有效率分别为 5 2 6 % ,6 4 6 % ,75 3% ,85 8% ,94 4 %。单用伊贝沙坦治疗 ,收缩压、舒张压、平均血压于第2周便开始明显下降 ,此后 ,随治疗时间的延长 ,血压不断下降 ,降压治疗的最大效应发生在第 12周。整个治疗过程无严重副作用发生。结论 伊贝沙坦治疗轻、中度原发性高血压病人安全有效 ,其疗效在不同年龄及不同体重指数的病人之间无明显差别。

Objectives To observe the efficacy and tolerability of irbesartan in patients with mild moderate essential hypertension. Methods 186 patients with mild moderate essential hypertension were recruited. All patients were treated with irbesartan for 12 weeks. Results After 2,4,6,8,12 weeks of treatment, prominent efficacy rate were 40 3%, 47 3%, 54 4%, 63 2%, 71 1% respectively, efficacy rate were 12 3%, 17 3%, 20 9%, 22 6%, 23 3% respectively, total efficacy rate were 52 6%, 64 6%, 75 3%, 85 8%, 94 4% respectively. A significant reduction in systolic and diastolic and mean blood pressure was found after only two weeks of therapy with irbesartan. The longer irbesartan was used, the lower reduction of blood pressure was found. The lowest reduction of blood pressure was found after 12 weeks of therapy with irbesartan. There were no serious adverse event during 12 weeks of therapy. Conclusions The antihypertensive treatment with irbesartan is effective and safety in the most mild moderate essential hypertension. The antihypertensive efficacy of irbesartan is similar in patients with different ages and different body mass index.